Real-time Estimate
Cboe BZX
12:08:42 2024-05-15 pm EDT
5-day change
1st Jan Change
51.86
USD
+3.63%
-0.61%
+8.49%
Sales 2024 *
-
Sales 2025 *
-
Capitalization
464M
Net income 2024 *
-83M
Net income 2025 *
-93M
EV / Sales 2024 *
-
Net cash position
2024
*
-
Net cash position
2025
*
-
EV / Sales 2025 *
-
P/E ratio 2024 *
-5.34
x
P/E ratio 2025 *
-5.03
x
Employees
102
Yield 2024 *
-
Yield 2025 *
-
Free-Float
93.49%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating
11:38am
MT
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer
May. 14
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Apr. 24
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Apr. 24
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Apr. 24
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Apr. 24
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Apr. 24
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Apr. 24
MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing
Apr. 24
MT
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc.
Apr. 21
CI
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P.
Apr. 16
CI
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept
Mar. 28
MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk
Mar. 27
MT
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 26
CI
North American Morning Briefing : Stocks Struggle After New Records
Mar. 22
DJ
More news
1 day +3.82%
1 week -0.61%
Current month -8.43%
1 month -30.08%
3 months -3.53%
6 months +19.79%
Current year +8.49%
More quotes
Date
Price
Change
Volume
24-05-15
52
+3.90%
11 841
24-05-14
50.05
-0.38%
27,027
24-05-13
50.24
-1.49%
50,951
24-05-10
51
-7.07%
25,832
24-05-09
54.88
+4.89%
32,545
Delayed Quote
Nasdaq, May 15, 2024 at 11:14 am EDT
More quotes
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cellâs natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify oneâs genome. The Company's focus areas include the liver and central nervous system (CNS).
More about the company
Last Close Price
50.05
USD
Average target price
130
USD
Spread / Average Target
+159.74%
Consensus
1st Jan change
Capi.
+8.49% 464M +26.60% 49.18B +0.58% 42.11B +50.47% 40.37B -5.26% 28.85B +13.70% 26.09B -22.36% 18.71B +8.12% 13.26B +32.10% 12.32B +0.13% 11.99B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1